人增生性瘢痕组织内下丘脑—垂体—肾上腺皮质轴成分的表达

目的 探讨增生性瘢痕组织中下丘脑-垂体-肾上腺皮质(HPA)轴成分的表达及意义.方法 应用实时荧光定量PCR法,检测人增生性瘢痕(12例)和正常皮肤(7例)组织中HPA轴的活性物质促肾上腺皮质素释放激素(CRH)、促肾上腺皮质素释放激素受体1(CRH-R1)、阿片-促黑素细胞皮质素原(POMC)、黑素皮质素受体2(MC-2R)以及糖皮质激素受体α(GR-α)的mRNA表达差异,免疫组织化学法观察CRH、CRH-R1、促肾上腺皮质激素(ACTH)、MC-2R以及GR-α的分布差异.对数据进行独立样本t检验. 结果 PCR结果显示,增生性瘢痕组织标本中CRH、CRH-R1、POMC及GR-α的mRNA表达分别为3.1±0.8、0.05±0.03、0.020±0.007、0.0000±0.0010,均低于正常皮肤组织的20.6±4.7、0.30±0.12、0.060±0.020、0.0200±0.0070,差异有统计学意义(t值为2.10-4.75,P值均小于0.05);但2种组织中MC-2R mRNA表达水平接近(t=1.48,P=0.15).免疫组织化学法检测结果显示,CRH,CRH-R1、ACTH、MC-2R以及GR-α分布于瘢痕组织的表皮基底层、真皮层的Fb和汗腺管壁中.在正常皮肤组织中阳性细胞除分布于上述部位外,还可见于毛囊和皮脂腺. 结论 增生性瘢痕形成与组织中HPA轴的活性物质表达降低有关.     

褪黑激素对增生性瘢痕成纤维细胞分泌转化生长因子β1的影响及其机制

目的 研究褪黑激素对增生性瘢痕Fb分泌TGF-β1的影响及机制. 方法 采用组织块法分离培养人增生性瘢痕Fb,按随机数字表法将细胞分为褪黑激素组、褪黑激素+Luzindole(褪黑激素受体拮抗剂)组、Luzindole组和对照组(仅以细胞培养液培养),前3组每孔细胞分别添加相应物质与细胞培养液培养,褪黑激素终浓度为1×10-3 mmol/L、Luzindole终浓度为1 mmol/L.每组10个复孔.培养24 h,采用ELISA法检测细胞培养上清液中TGF-β1含量,实时荧光定量PCR检测细胞TGF-β1、Smad 7和Rho激酶(ROCK) mRNA表达.对数据进行单因素方差分析或LSD-t检验或Kruskal-Wallis检验,组间比较采用Nemneyi法. 结果 褪黑激素组Fb上清液中TGF-β1含量为(2.8±2.4) pg/mL,低于褪黑激素+Luzindole组的(23.9±2.7)pg/mL、对照组的(28.9±2.0) pg/mL和Luzindole组的(24.9 ±2.8)pg/mL(F=94.58,P＜0.05).褪黑激素组细胞TGF-β1 mRNA表达量为11.9±1.2,明显低于其他组(F=20.79,P＜0.05);褪黑激素+Luzindole组TGF-β1mRNA表达量(14.9±1.8)与对照组(17.2±0.6)比较差异无统计学意义(t=0.806,P＞0.05).褪黑激素组Fb Smad 7 mRNA表达量(0.076±0.080)明显高于对照组(0.023±0.024)、褪黑激素+Luzindole组(0.026 ±0.026)、Luzindole组(0.037±0.021),x 2=9.567,P＜0.05.褪黑激素组ROCK mRNA的表达量明显低于对照组(0.002 30±0.002 70)、褪黑激素+Luzindole组(0.001 30±0.001 20)和Luzindole组(0.001 10 ±0.001 20),x 2=9.420,P＜0.05. 结论 褪黑激素可通过与受体结合,上调瘢痕Fb中Smad 7表达、下调ROCK表达,从而抑制增生性瘢痕Fb表达TGF-β1.     

褪黑激素对人增生性瘢痕成纤维细胞增殖和凋亡的影响

目的 探讨褪黑激素对人增生性瘢痕Fb增殖和凋亡的影响与机制. 方法 采用组织块法分离培养人增生性瘢痕Fb.按随机数字表法将细胞分为低、中、高浓度组和对照组.前3组细胞分别采用含1 × 10-5、1×10-3、1 mmol/L褪黑激素的培养液培养,对照组不加褪黑激素常规培养.处理后24 h进行如下检测:对各组细胞进行形态学观察;用四氮唑复合物( XTT)-硫酸酚嗪甲酯(PMS)比色法检测细胞增殖活性;对细胞行膜联蛋白V-异硫氰酸荧光素(FITC)和碘化丙啶(PI)双染色后,用流式细胞仪分析细胞周期和凋亡情况;荧光定量RT-PCR法检测细胞周期蛋白E(cyclin E)、p53和Fas mRNA表达量.对数据行方差分析和LSD检验. 结果 形态学观察显示,对照组Fb为长梭形,呈集落分布;3个浓度组Fb随着褪黑激素浓度升高,细胞逐渐分散,胞体变形缩小,胞膜皱缩,核质比例减小.对照组、低浓度组、中浓度组、高浓度组Fb增殖活性(吸光度值)依次下降,分别为1.79±0.10、1.49±0.15、1.24±0.20、0.92±0.09(F=67.61,P ＜0.05);S期细胞百分比依次下降,分别为(16.9±1.3)％、(10.6±1.1)％、(6.1±1.2)％、(3.2±0.8)％(F=286.10,P ＜0.05);G2/M期细胞百分比依次下降,分别为(16.7±1.6)％、(13.5±1.1)％、(9.8±1.0)％(6.0±0.7)％(F=162.69,P＜0.05);早、晚期凋亡细胞百分比依次升高(F值分别为424.05、236.44,P值均小于0.05).对照组、低浓度组、中浓度组、高浓度组细胞cyclin E的mRNA表达量依次下降,分别为2.90±0.30、1.58±0.21、0.90±0.20、0.24±0.12(F=266.79,P＜0.05);p53和Fas mRNA表达量依次升高(F值分别为10.11、12.03,P值均小于0.05). 结论 褪黑激素可通过影响细胞cyclin E、p53和Fas基因的表达,抑制增生性瘢痕Fb增殖并诱导该细胞凋亡.     

健康教育在瘢痕增生病人出院后的应用

[目的]探讨健康教育在瘢痕增生病人出院后的应用。[方法]将120例瘢痕增生出院病人随机分为对照组和观察组,每组60例,对照组行常规指导,未实施电话回访,观察组病人出院后1个月、3个月、6个月给予有针对性的、应答式电话回访式健康教育。比较两组病人健康教育达标率、满意度、6个月后瘢痕改善情况。[结果]观察组病人健康教育达标率、满意度、6个月后瘢痕改善情况均优于对照组(P<0.05)。[结论]通过健康教育可以使病人掌握正确的康复知识、预防和改善病人瘢痕增生的程度、提高病人满意度。     

增生性瘢痕组织中褪黑素受体的表达

目的 检测人增生性瘢痕组织和正常皮肤中褪黑素受体含量的差异,探讨其意义.方法 人增生性瘢痕组织和正常皮肤各10例,免疫组化检测组织中褪黑素受体GPR50的表达,荧光定量PCR(SYBR Green)检测组织中褪黑素受体MT1、MT2 mRNA含量,并将PCR阳性产物基因测序.结果 免疫组化显示褪黑素受体GPR50表达于细胞膜和细胞质,正常皮肤表皮基底层细胞、毛囊和汗腺均有褪黑素受体阳性表达,增生性瘢痕组织表皮、残留的毛囊和汗腺内也存在褪黑素受体表达;同时发现增生性瘢痕真皮成纤维细胞有广泛褪黑素受体阳性表达,而正常皮肤组织中则少见表达.荧光定量PCR显示增生性瘢痕组织中MT1、MT2 mRNA含量分别为(1.16584 4±0.21829)和(0.99550 ±0.14624)拷贝数/μl cDNA,正常皮肤中为(0.99081±0.26485)和(0.77083±0.15927)拷贝数/μl cDNA,增生性瘢痕组织中MT1、MT2 mRNA含量均高于正常皮肤(P相似文献   

增生性瘢痕组织中褪黑素受体的表达

Objective To investigate the expression and its significance of melatonin receptor in human hypertrophic scarring. Methods The expression of melatonin receptor GPR50 was detected with immunohistochemistiy and the melatonin receptors( MT1 、MT2)mRNA were assessed with RT-PCR method in 10 cases of human hypertrophic scar and normal skin. The positive production was sequenced with auto sequencing instrument. Results Positive signals of melatonin receptor could be found in the cell membrane and cytoplasm. The melatonin receptor GPR50 was located in the epithelial basal cells, sweat gland cells and hair follicle in both hypertrophic scar and normal skin. The melatonin receptor GPR50 was extensively expressed in fibroblasts of hypertrophic scar, but not in fibroblasts in normal skin. RT-PCR showed that the expression of melatonin receptor( MT1, MT2 ) mRNA in hypertrophic scar was significantly higher than that in normal skin( P <0. 05). In normal skin and hypertrophic scar group, the expression of MT1 mRNA was higher than MT2 mRNA ( P < 0. 05 ) . In normal skin and hypertrophic scar group, the expression of MT1 mRNA was 0.99081 ±0.26485 and 1.16584 ±0.21829 copy number/μl cDNA, respectively;the expression of MT2 mRNA was 0. 77083 ±0. 15927and 0. 99550 ±0. 14624 copy number/ μl cDNA, respectively. Sequencing results indicated that the positive product coincided with cDNA of human melatonin receptor in GeneBank. Conclusions Positive expression of melatonin receptor can be found in human hypertrophic scar and normal skin, but it is higher in scar. The over expression of melatonin receptor in hypertrophic scar may be related to the development of hypertrophic scar.     

增生性瘢痕组织中褪黑素受体的表达

Objective To investigate the expression and its significance of melatonin receptor in human hypertrophic scarring. Methods The expression of melatonin receptor GPR50 was detected with immunohistochemistiy and the melatonin receptors( MT1 、MT2)mRNA were assessed with RT-PCR method in 10 cases of human hypertrophic scar and normal skin. The positive production was sequenced with auto sequencing instrument. Results Positive signals of melatonin receptor could be found in the cell membrane and cytoplasm. The melatonin receptor GPR50 was located in the epithelial basal cells, sweat gland cells and hair follicle in both hypertrophic scar and normal skin. The melatonin receptor GPR50 was extensively expressed in fibroblasts of hypertrophic scar, but not in fibroblasts in normal skin. RT-PCR showed that the expression of melatonin receptor( MT1, MT2 ) mRNA in hypertrophic scar was significantly higher than that in normal skin( P <0. 05). In normal skin and hypertrophic scar group, the expression of MT1 mRNA was higher than MT2 mRNA ( P < 0. 05 ) . In normal skin and hypertrophic scar group, the expression of MT1 mRNA was 0.99081 ±0.26485 and 1.16584 ±0.21829 copy number/μl cDNA, respectively;the expression of MT2 mRNA was 0. 77083 ±0. 15927and 0. 99550 ±0. 14624 copy number/ μl cDNA, respectively. Sequencing results indicated that the positive product coincided with cDNA of human melatonin receptor in GeneBank. Conclusions Positive expression of melatonin receptor can be found in human hypertrophic scar and normal skin, but it is higher in scar. The over expression of melatonin receptor in hypertrophic scar may be related to the development of hypertrophic scar.     

皮肤下丘脑-垂体-肾上腺皮质轴与创面愈合

下丘脑-垂体-肾上腺皮质(HPA)轴是机体应激过程中主要的神经-内分泌调节系统之一。皮肤作为人体的最大器官,被证实也具有与中枢HPA轴相似的外周神经-内分泌调节功能。在皮肤组织中,促肾上腺皮质释放激素、促肾上腺皮质释放激素受体和促前阿片黑素细胞皮质激素的基因表达和糖皮质激素均可被检查到。多项实验提示,HPA轴相应的激素在皮肤应急过程中起重要作用,并由此推论其对皮肤损伤、感染或免疫失调所激发的创面愈合过程有调节作用。     

褪黑素对增生性瘢痕成纤维细胞生物学活性的调控

目的 探讨褪黑素对增生性瘢痕成纤维细胞生物学活性的调控.方法 分离培养增生性瘢痕成纤维细胞,采用四氮唑复合物/硫酸酚嗪甲酯(XTT/PMS)法检测细胞增殖活性,酶联免疫吸附实验(ELISA)检测细胞培养上清液中β1转化生长因子(TGF-β1)含量和荧光定量聚合酶链反应(PCR)检测细胞α平滑肌肌动蛋白(α-SMA)、胶原Ⅰ和胶原ⅢmRNA表达,评价褪黑素和褪黑素受体拮抗剂(luzindole)对增生性瘢痕成纤维细胞生物学活性的影响.结果 褪黑素抑制增生性瘢痕成纤维细胞的增殖,抑制效果呈浓度依赖性(P＜0.05);高浓度褪黑素(10-3 mmol/L)可降低增生性瘢痕成纤维细胞产生TGF-β1 (P＜0.05)和α-SMA mRNA、胶原Ⅰ mRNA的表达(P＜0.05);褪黑素受体拮抗剂能阻断褪黑素对细胞产生TGF-β1和α-SMA、胶原Ⅰ mRNA表达的抑制作用(P＜0.05);但褪黑素对该细胞胶原ⅢmRNA表达无影响(P＞0.05).结论 褪黑素可通过与受体结合调控增生性瘢痕成纤维细胞的生物学活性.